Rockwell Medical, Inc. (RMTI)
| Market Cap | 28.18M -14.6% |
| Revenue (ttm) | 67.68M -30.7% |
| Net Income | -5.56M |
| EPS | -1.49 |
| Shares Out | 3.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,327 |
| Open | 7.16 |
| Previous Close | 7.16 |
| Day's Range | 7.10 - 7.44 |
| 52-Week Range | 4.89 - 21.00 |
| Beta | 1.62 |
| Analysts | Buy |
| Price Target | 30.00 (+320.17%) |
| Earnings Date | Aug 13, 2026 |
About RMTI
Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic a... [Read more]
Financial Performance
In 2025, Rockwell Medical's revenue was $69.26 million, a decrease of -31.76% compared to the previous year's $101.49 million. Losses were -$5.47 million, 599.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for RMTI stock is "Buy." The 12-month stock price target is $30.0, which is an increase of 320.17% from the latest price.
News
Rockwell Medical Advances Quality and Regulatory Leadership
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Brian Cox joins Rockwell Medical as VP, Quality and Regulatory Compliance, bringing more than 20 years' healthcare experience to the Com...
Rockwell Medical regains compliance with Nasdaq listing rules
Rockwell Medical (RMTI) announced that it has received notice from The Nasdaq Stock Market that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule…
Rockwell Medical Regains Compliance with Nasdaq Listing Requirements
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical received notice from Nasdaq that it regained compliance with the minimum bid price requirement under Nasdaq Listing Rul...
Rockwell Medical to Release Second Quarter 2026 Results on Thursday, August 13, 2026
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026.
Rockwell Medical target adjusted to $20 at H.C. Wainwright after reverse split
H.C. Wainwright analyst Raghuram Selvaraju adjusted the firm’s price target on Rockwell Medical (RMTI) to $20 from $2 and keeps a Buy rating on the shares after the company’s recently…
Rockwell Medical trading halted, news pending
19:50 EDT Rockwell Medical (RMTI) trading halted, news pending
Rockwell Medical announces 1-for-10 reverse stock split
Rockwell Medical (RMTI) announced that its Board of Directors has authorized a 1-for-10 reverse split of the company’s issued and outstanding common stock. The Board received approval at the company’s...
Rockwell Medical Announces 1-for-10 Reverse Stock Split
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical's Board of Directors has authorized a 1-for-10 reverse split of the Company's issued and outstanding common stock.
Rockwell Medical Transcript: AGM 2026
The meeting covered director elections, executive compensation, auditor ratification, and a reverse stock split amendment, all of which were approved by strong majorities. No questions were raised by stakeholders, and final voting results will be filed with the SEC.
Rockwell Medical renews and extends purchase agreement with aQua Dialysis
Rockwell Medical (RMTI) announced that the Company has renewed and extended its product purchase agreement with aQua Dialysis a leading independent provider of in-center hemodialysis and home dialysis...
Rockwell Medical Renews Product Purchase Agreement with aQua Dialysis
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will supply aQua Dialysis with liquid and dry, acid and bicarbonate hemodialysis concentrates and other essential dialy...
Rockwell Medical signs new product purchase agreement with Heritage Dialysis
Rockwell Medical (RMTI) announced that the company entered into a three-year product purchase agreement with Heritage Dialysis, a Michigan-based family-owned company comprised of dialysis professional...
Rockwell Medical Signs New 3-Year Product Purchase Agreement with Heritage Dialysis
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will supply Heritage Dialysis with a portfolio of hemodialysis products including PureCart, RenalPure, SteriLyte and ot...
Rockwell Medical Proxy statement: Proxy filing
Rockwell Medical filed a proxy statement on May 11, 2026, providing details for shareholder voting and corporate governance matters.
Rockwell Medical Earnings Call Transcript: Q1 2026
Q1 2026 saw improved gross margin and stable gross profit despite lower sales, with positive trends in adjusted EBITDA and net income. Guidance for 2026 projects $70–$75M in sales, 18–22% gross margin, and positive cash flow, supported by operational efficiencies and international growth.
Rockwell Medical Earnings release: Q1 2026
Rockwell Medical released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Rockwell Medical Quarterly report: Q1 2026
Rockwell Medical has published its Q1 2026 quarterly earnings report on May 7, 2026.
Rockwell Medical Slides: Q1 2026
Rockwell Medical has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Rockwell Medical reports Q1 adjusted EPS (1c) vs. (1c) last year
Reports Q1 revenue $17.3M vs. $18.9M last year. “Our financial and operational performance in the first quarter 2026 builds on the positive trajectory we have established across our key financial…
Rockwell Medical sees 2026 revenue $70.0M-$75.0M, consensus $73.77M
Sees 2026 adjusted EBITDA $1.0M-$2.0M.
Rockwell Medical Announces First Quarter 2026 Results and Additional 2026 Guidance with Focus on Profitability
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical 2026 Guidance is centered around strengthening revenue, expanding gross margin, and generating positive Adjusted EBITDA...
Rockwell Medical Proxy statement: Proxy filing
Rockwell Medical filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Rockwell Medical Proxy statement: Proxy filing
Rockwell Medical filed a proxy statement on April 20, 2026, providing details for shareholder voting and corporate governance matters.
Rockwell Medical to Release First Quarter 2026 Results on Thursday, May 7, 2026
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026.
Rockwell Medical price target lowered to $2 from $2.50 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Rockwell Medical (RMTI) to $2 from $2.50 and keeps a Buy rating on the shares. The firm cites the company’s “more modest”…